SIWA Therapeutics
They founded SIWA in 2006 to develop biological therapies, including their proprietary humanized monoclonal antibody, SIWA 318H, for slowing or reversing the aging process through the removal of SCs. SCs are causally implicated in age-related dysfunction and in degenerative disease. These cells act primarily by secreting substances which interfere with normal functions of other cells; thus, removing them has been shown to improve healthspan and lifespan.
Domain
siwatherapeutics.com
Country
United StatesIndustry
BiotechnologyEmployees
1-10
Last Funding
$1.6M
Founded
2005
Tech Stack (18 technologies)
Frequently Asked Questions
What technologies does SIWA Therapeutics use?+
SIWA Therapeutics uses 18 technologies including Elementor, Font Awesome, OWL Carousel.
What industry is SIWA Therapeutics in?+
SIWA Therapeutics operates in the Biotechnology industry.
Where is SIWA Therapeutics based?+
SIWA Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026